(Q47426446)

16 January 2018

title

How low is the alpha/beta ratio for prostate cancer? (English)

1 reference

16 January 2018

How low is the α/β ratio for prostate cancer? (English)

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)01455-X

24 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)01455-X

24 March 2024

author name string

Henk B. Kal

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575844

24 March 2024

Marion P. R. Van Gellekom

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575844

24 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

16 January 2018

15 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14575844

full work available at URL

24 March 2024

https://api.elsevier.com/content/article/PII:S036030160301455X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)01455-X

https://api.elsevier.com/content/article/PII:S036030160301455X?httpAccept=text/plain

24 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)01455-X

International Journal of Radiation Oncology Biology Physics

24 March 2024

published in

1 reference

16 January 2018

volume

57

1 reference

16 January 2018

issue

4

1 reference

16 January 2018

page(s)

1116-1121

1 reference

16 January 2018

Fractionation and protraction for radiotherapy of prostate carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Is alpha/beta for prostate tumors really low?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

How low is the alpha/beta ratio for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Toward optimal external-beam fractionation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Hypofractionation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

The ESTRO Breur lecture. Cellular sensitivity to low dose-rate irradiation focuses the problem of tumour radioresistance

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

The influence of brachytherapy dose heterogeneity on estimates of / for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901455-X

7 January 2021

A comment on proliferation rates in human prostate cancer

series ordinal

14

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)01455-X

24 March 2024

Identifiers

1 reference

16 January 2018

1 reference

16 January 2018